GLAXOSMITHKLINE PLC Form 6-K April 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 17 April 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

GlaxoSmithKline plc (the 'Company') Transaction notification

1.	1. Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Ms E Walmsley		
,	Position/status	Chief Executive Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance	e market participant, auction		
	platform, auctioneer or auction monitor Name	Clave Smith Vline pla		
a) b)	LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793		
0)				
2	Details of the transaction(s): section to b			
3.	······································			
	place where transaction(s) has been cond			
		Ordinary shares of 25 pence		
a)	Description of the financial instrument	each ('Ordinary Shares')		
	1	ISIN: GB0009252882		
		Increase in notional interest		
b)	Nature of the transaction	in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. Price(s) Volume(s)		
b)	Nature of the transaction	the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.		
,	Nature of the transaction Price(s) and volume(s)	the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. Price(s) Volume(s)		
,		the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. Price(s) Volume(s) £14.296 3,639.339		

Aggregated information	
d)	16,583.050
Aggregated volume Price	£14.296

e) Date of the transaction	2018-04-12
f) Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associa	ted with then	n ('PCA')
a)	Name	Mr R G Cor	nnor
b)	Position/status	President, C	
0)		Manufactur	ing & Supply
c)	Initial notification/ amendment	Initial notifi	cation
2	Details of the issuer, emission allowance	e market parti	icipant, auction
2.	platform, auctioneer or auction monitor	-	-
a)	Name	GlaxoSmith	Kline plc
b)	LEI	5493000HZ	TVUYLO1D793
	Details of the transaction(s): section to b	e repeated fo	or (i) each type of
3.	instrument; (ii) each type of transaction;		e; and (iv) each
	place where transaction(s) has been conc		
		•	ares of 25 pence
a)	Description of the financial instrument		nary Shares')
		ISIN: GB00	09252882
		т.	
			notional interest
	Nature of the transaction	in Ordinary Shares following	
		the re-investment of	
b)		dividends paid to shareholders on 12 April	
			•
			dinary Shares held
		in the Comp	e Share Plan.
		Price(s) £14.296	Volume(s) 2,125.159
		£14.290	2,123.139
()	Price(s) and volume(s)	£14.296	2,031.057
C)	Thee(s) and volume(s)	214.290	2,051.057
		£14.296	2,793.963
		211.270	2,795.905
1	Aggregated information		
d)	A some soft of violance Drive	6,950.178	
	Aggregated volume Price	£14.296	
e)	Date of the transaction	2018-04-12	
		T 1 C	

- f) Place of the transaction London Stock Exchange (XLON)
- 1. Details of PDMR/person closely associated with them ('PCA')
 - Mr L Debruyne

Initial notification

President, Global Vaccines

b) Position/status

a) Name

c) Initial notification/

amendment

- 2. Details of the issuer, emission allowance market participant, auction
- ². platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.	
	Price(s) Volume(s)	
	£14.296 534.931	
c) Price(s) and volume(s)	£14.296 1,523.594	
	£14.296 2,121.579	

	Aggregated information			
d)		4,180.105		
	Aggregated volume Price	£14.296		
e)	Date of the transaction	2018-04-12		

e)	Date of the transaction	2018-04-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr L Miels	
b)	Position/status	President, Global Pharmaceuticals	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	market participant, auction	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	

3.	Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	•	ares of 25 pence nary Shares') 009252882	
b)	Nature of the transaction	in Ordinary the re-inves dividends p shareholder 2018 on Ord in the Comp	aid to s on 12 April dinary Shares held pany's e Share Plan.	
c)	Price(s) and volume(s)	£14.296 £14.296 £14.296	3,489.352 2,410.334 3,628.919	

	Aggregated information	9,528.606
d)		£14.296
	Aggregated volume Price	

e)	Date of the transaction	2018-04-12
f)	Place of the transaction	London Stock Exchange
T)		(XLON)

- 1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
 b) Position/status Chief Financial Officer
 c) Initial notification/ amendment
 c) Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYL01D793
- Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.	
	Price(s)	Volume(s)
	£14.296	2,489.892
c) Price(s) and volume(s)	£14.296	3,908.186
	£14.296	3,224.047
	£14.296	3,852.243

	Aggregated information		
d)		13,474.367	
-	Aggregated volume Price	£14.296	

e)	Date of the transaction	2018-04-12
f)	Place of the transaction	London Stock Exchange (XLON

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr N Hirons	
b)	Position/status	SVP, Global Ethics & Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each	
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to	

c)	Price(s) and volume(s)	2018 on Ord in the Comp	s on 12 April linary Shares h any's e Share Plan. Volume(s) 876.631 748.274 1,036.207	eld
d) e)	Aggregated information Aggregated volume Price Date of the transaction	2,661.111 £14.296 2018-04-12		
	Place of the transaction		ck Exchange	
a)	Details of PDMR/person closely associa Name Position/status Initial notification/ amendment Details of the issuer, emission allowance auctioneer or auction monitor	Mr D S Red Chief Strate	fern gy Officer cation	platform,
	Name LEI Details of the transaction(s): section to b	e repeated fo	TVUYLO1D7 r (i) each type	of instrument;
a)	Description of the financial instrument	Ordinary sha ('Ordinary S ISIN: GB00		e each
,	Nature of the transaction Price(s) and volume(s)	Shares follo dividends pa April 2018 d	notional interes wing the re-inv aid to sharehold on Ordinary Sh y's Performanc	vestment of ders on 12 ares held in
		£14.296		1,453.809
		£14.296		1,915.390

7

	A		
4)	Aggregated information		
d)	Aggregated volume Price	4,909.931	
		£14.296	
e)	Date of the transaction	2018-04-12	
	Place of the transaction	London Stock Exchange (XLON	1)
1.	Details of PDMR/person closely associa	ted with them ('PCA')	
	Name	Ms C Thomas	
b)	Position/status	SVP, HR	
	Initial notification/		
c)	amendment	Initial notification	
2.	Details of the issuer, emission allowance	e market participant, auction platf	orm,
	auctioneer or auction monitor		
	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii		
3.	each type of transaction; (iii) each date;	and (iv) each place where transac	tion(s) has
	been conducted		
		Ordinary shares of 25 pence eac	h ('Ordinary
a)	Description of the financial instrument	Shares')	
,	L	ISIN: GB0009252882	
		Increase in notional interest in C)rdinary
		Shares following the re-investme	-
b)	Nature of the transaction	dividends paid to shareholders o	
0)		2018 on Ordinary Shares held in	-
		Company's Performance Share I	
		Price(s)	Volume(s)
		£14.296	1,939.201
			,
c)	Price(s) and volume(s)	£14.296	1,603.457
		£14.296	2,171.486
	Aggregated information		
d)		5,714.144	
/	Aggregated volume Price	£14.296	
e)	Date of the transaction	2018-04-12	

e)	Date of the transaction	2018-04-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')				
a)					
b)			President, Global Affairs		
0)	Initial				
c)		Initial notification			
	Details of the is	suer, emissio	n allowance		
2.	market participa				
2.	auctioneer or au	-			
a)	Name	GlaxoSmithKline plc			
b)	LEI				
0)			5493000HZTVUYLO1D793 ansaction(s): section to be		
2	repeated for (i)	• •			
3.	2 I				
	· / I	where transac	ction(s) has been		
	conducted				
	Description of	•	ares of 25 pence		
a)	•	each ('Ordin	•		
<i>a)</i>	instrument	ISIN: GB00	09252882		
	mstrument				
		Increase in r	otional interest		
		in Ordinary Shares following			
		the re-investment of			
1 \	Nature of the	dividends paid to			
b)	transaction	•	on 12 April		
		2018 on Ordinary Shares held			
		in the Comp	•		
		Performance	•		
		Price(s)			
		£14.296	1,115.711		
		214.290	1,113./11		
c)	Price(s) and volume(s)	£14.296	1,004.831		
		£14.296	1,365.746		
		217.270	1,505.740		
	Aggragated				
	Aggregated information				
۲ ۴	mormation	2 406 200			
d)	A	3,486.288			
	Aggregated	£14.296			
	volume Price				
e)	Date of the	2018-04-12			
,	transaction		1 - 1		
f)	Place of the	London Stock Exchange			
,	transaction	(XLON)			

1.	Details of PDMR/person closely associa	ted with them ('PCA')
	Name	Mrs V A Whyte
b)	Position/status	Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance	e market participant, auction
	platform, auctioneer or auction monitor	
	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793
0)	Details of the transaction(s): section to b	
3.	instrument; (ii) each type of transaction;	
	place where transaction(s) has been cond	
		Ordinary shares of 25 pence
a)	Description of the financial instrument	each ('Ordinary Shares')
	•	ISIN: GB0009252882
		Increase in notional interest
		in Ordinary Shares following
		the re-investment of
h)	Nature of the transaction	dividends paid to
0)		shareholders on 12 April
		2018 on Ordinary Shares held in the Company's
		Performance Share Plan.
		Price(s) Volume(s)
	Drive (a) and we have a (a)	£14.296 212.997
C)	Price(s) and volume(s)	£14.296 199.988
		£14.296 189.843
	Aggregated information	
d)		
	Aggregated volume Price	602.829
		£14.296
e)	Date of the transaction	2018-04-12
	Place of the transaction	London Stock Exchange
f)		(XLON)
1.	Details of PDMR/person closely associa	ted with them ('PCA')
a)	Name	Mr B McNamara
	Position/status	CEO, GSK Consumer
,	Initial notification/	Healthcare
c)	amendment	Initial notification
		•

- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc

b) 3.	LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	e repeated fo (iii) each dat	•••
a)	Description of the financial instrument	American D ('ADSs') ISIN: US37	Depositary Shares
b)	Nature of the transaction	in ADSs fol re-investme paid to share April 2018 of	notional interest lowing the nt of dividends eholders on 12 on ADSs held in ny's Performance
c)	Price(s) and volume(s)	Price(s) \$40.62 \$40.62 \$40.62	Volume(s) 866.909 1,399.614 1,727.388

Aggregated information	
d)	3,993.911
Aggregated volume Price	\$40.62

e)	Date of the transaction	2018-04-12
f)	Place of the transaction	New York Stock Exchange
I)		(XNYS)

1.	Details of PDMR/	person closely	associated	with them	('PCA')

1.	Details of PDMR/person closely associa	ted with them ('PCA')	
a)	Name	Mr D E Troy	
b)	Position/status	SVP & General Counsel	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance	e market participant, auction	
∠.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to b	be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction;	(iii) each date; and (iv) each	
	place where transaction(s) has been cond	ducted	
		American Depositary Shares	
a)	Description of the financial instrument	('ADSs')	
		ISIN: US37733W1053	
b)	Nature of the transaction	Increase in notional interest	
		in ADSs following the	
		re-investment of dividends	

	paid to sha	areholders on 12
	April 2018	8 on ADSs held in
	the Compa	any's Performance
	Share Plan	1.
	Price(s)	Volume(s)
a) $\mathbf{Price}(a)$ and $\mathbf{vel}(\mathbf{rre}(a))$	\$40.62	1,775.668
c) Price(s) and volume(s)	\$40.62	1,559.572

	Aggregated information	
d)		3,335.240
	Aggregated volume Price	\$40.62
e)	Date of the transaction	2018-04-12

e)	Date of the transaction	2018-04-12
f)	Place of the transaction	New York Stock Exchange
1)		(XNYS)

1.	Details of PDMR/person closely associa	ted with them (('PCA')
a)	Name	Mr H Barron	
1 \		Chief Scientif	ic Officer and
b)	Position/status	President, R&	D
``	Initial notification/		
c)	amendment	Initial notifica	ition
2.	Details of the issuer, emission allowance	market partici	pant, auction
Ζ.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithK	line plc
b)	LEI	5493000HZT	VUYLO1D793
	Details of the transaction(s): section to b	e repeated for ((i) each type of
3.	instrument; (ii) each type of transaction;		
	place where transaction(s) has been cond		
			oositary Shares
``		('ADSs')	-
a)	Description of the financial instrument	ISIN: US3773	3W1053
		Increase in no	tional interest
		in ADSs follo	wing the
		re-investment	of dividends
b)	Nature of the transaction	paid to shareh	olders on 12
		-	ADSs held in
		•	s Performance
		Share Plan.	
		Price(s) V	/olume(s)
c)	Price(s) and volume(s)		,711.539
	Aggregated information	n/a (single tran	
d)		× C	<i>,</i>
/	Aggregated volume Price		
e)	Date of the transaction	2018-04-12	

12

f) Place of the transaction

New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associa	ted with them ('PCA')
a)	Name	Ms K Terrell
		Chief Digital & Technology
b)	Position/status	Officer
	Tuitial undification /	Officer
c)	Initial notification/	Initial notification
	amendment	
2.	Details of the issuer, emission allowance	e market participant, auction
2.	platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to b	e repeated for (i) each type of
3.	instrument; (ii) each type of transaction;	
	place where transaction(s) has been cond	
		American Depositary Shares
		('ADSs')
a)	Description of the financial instrument	(ADSS) ISIN: US37733W1053
		13IIN: US37733W1033
		Y Y Y Y Y
		Increase in notional interest
		in ADSs following the
		in ADSs following the re-investment of dividends
b)	Nature of the transaction	in ADSs following the
b)	Nature of the transaction	in ADSs following the re-investment of dividends
b)	Nature of the transaction	in ADSs following the re-investment of dividends paid to shareholders on 12
b)	Nature of the transaction	in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in
,		in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan.
,	Nature of the transaction Price(s) and volume(s)	in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. Price(s) Volume(s)
,	Price(s) and volume(s)	in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. Price(s) Volume(s) \$40.62 1,432.209
c)		in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. Price(s) Volume(s)
,	Price(s) and volume(s) Aggregated information	in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. Price(s) Volume(s) \$40.62 1,432.209
c) d)	Price(s) and volume(s) Aggregated information Aggregated volume Price	in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. Price(s) Volume(s) \$40.62 1,432.209 n/a (single transaction)
c)	Price(s) and volume(s) Aggregated information Aggregated volume Price Date of the transaction	in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. Price(s) Volume(s) \$40.62 1,432.209 n/a (single transaction) 2018-04-12
c) d)	Price(s) and volume(s) Aggregated information Aggregated volume Price	in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. Price(s) Volume(s) \$40.62 1,432.209 n/a (single transaction) 2018-04-12 New York Stock Exchange
c) d) e)	Price(s) and volume(s) Aggregated information Aggregated volume Price Date of the transaction	in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. Price(s) Volume(s) \$40.62 1,432.209 n/a (single transaction) 2018-04-12

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc